Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol

Satoshi Akagi, Hiromi Matsubara, Katsumasa Miyaji, Etsuko Ikeda, Kazuhiro Dan, Naoto Tokunaga, Kenichi Hisamatsu, Mitsuru Munemasa, Yoshihisa Fujimoto, Tohru Ohe

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background Combination therapy has been proposed in treatment algorithms for idiopathic pulmonary arterial hypertension (IPAH), so the additional effects of bosentan in IPAH patients already treated with high-dose cpoprostcnol (EPO) was evaluated in the present study. Methods and Results Bosentan (62.5 mg twice daily) was administered to 8 IPAH patients already being treated with high-dose EPO (average dose 99.6 ± 43.4 ng · kg-1 · min-1). Hemodynamics were assessed at baseline and at 2 days and then 1 year after the initiation of bosentan. Because a remarkable elevation of mixed venous oxygen saturation was observed at the initiation of bosentan, the dosage of EPO was reduced in 7 patients (from 99,6 ± 43.4 to 82.8 ± 31.3 ng · kg-1 · minl, p

Original languageEnglish
Pages (from-to)1142-1146
Number of pages5
JournalCirculation Journal
Volume72
Issue number7
DOIs
Publication statusPublished - 2008
Externally publishedYes

Fingerprint

Epoprostenol
Hemodynamics
Oxygen
Familial Primary Pulmonary Hypertension
bosentan
Therapeutics

Keywords

  • Bosentan
  • Combination therapy
  • Epoprostenol
  • Idiopathic pulmonary arterial hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology

Cite this

Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. / Akagi, Satoshi; Matsubara, Hiromi; Miyaji, Katsumasa; Ikeda, Etsuko; Dan, Kazuhiro; Tokunaga, Naoto; Hisamatsu, Kenichi; Munemasa, Mitsuru; Fujimoto, Yoshihisa; Ohe, Tohru.

In: Circulation Journal, Vol. 72, No. 7, 2008, p. 1142-1146.

Research output: Contribution to journalArticle

Akagi, S, Matsubara, H, Miyaji, K, Ikeda, E, Dan, K, Tokunaga, N, Hisamatsu, K, Munemasa, M, Fujimoto, Y & Ohe, T 2008, 'Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol', Circulation Journal, vol. 72, no. 7, pp. 1142-1146. https://doi.org/10.1253/circj.72.1142
Akagi, Satoshi ; Matsubara, Hiromi ; Miyaji, Katsumasa ; Ikeda, Etsuko ; Dan, Kazuhiro ; Tokunaga, Naoto ; Hisamatsu, Kenichi ; Munemasa, Mitsuru ; Fujimoto, Yoshihisa ; Ohe, Tohru. / Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. In: Circulation Journal. 2008 ; Vol. 72, No. 7. pp. 1142-1146.
@article{c0d73eb1fd51485393bbc92a9c8f54cc,
title = "Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol",
abstract = "Background Combination therapy has been proposed in treatment algorithms for idiopathic pulmonary arterial hypertension (IPAH), so the additional effects of bosentan in IPAH patients already treated with high-dose cpoprostcnol (EPO) was evaluated in the present study. Methods and Results Bosentan (62.5 mg twice daily) was administered to 8 IPAH patients already being treated with high-dose EPO (average dose 99.6 ± 43.4 ng · kg-1 · min-1). Hemodynamics were assessed at baseline and at 2 days and then 1 year after the initiation of bosentan. Because a remarkable elevation of mixed venous oxygen saturation was observed at the initiation of bosentan, the dosage of EPO was reduced in 7 patients (from 99,6 ± 43.4 to 82.8 ± 31.3 ng · kg-1 · minl, p",
keywords = "Bosentan, Combination therapy, Epoprostenol, Idiopathic pulmonary arterial hypertension",
author = "Satoshi Akagi and Hiromi Matsubara and Katsumasa Miyaji and Etsuko Ikeda and Kazuhiro Dan and Naoto Tokunaga and Kenichi Hisamatsu and Mitsuru Munemasa and Yoshihisa Fujimoto and Tohru Ohe",
year = "2008",
doi = "10.1253/circj.72.1142",
language = "English",
volume = "72",
pages = "1142--1146",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "7",

}

TY - JOUR

T1 - Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol

AU - Akagi, Satoshi

AU - Matsubara, Hiromi

AU - Miyaji, Katsumasa

AU - Ikeda, Etsuko

AU - Dan, Kazuhiro

AU - Tokunaga, Naoto

AU - Hisamatsu, Kenichi

AU - Munemasa, Mitsuru

AU - Fujimoto, Yoshihisa

AU - Ohe, Tohru

PY - 2008

Y1 - 2008

N2 - Background Combination therapy has been proposed in treatment algorithms for idiopathic pulmonary arterial hypertension (IPAH), so the additional effects of bosentan in IPAH patients already treated with high-dose cpoprostcnol (EPO) was evaluated in the present study. Methods and Results Bosentan (62.5 mg twice daily) was administered to 8 IPAH patients already being treated with high-dose EPO (average dose 99.6 ± 43.4 ng · kg-1 · min-1). Hemodynamics were assessed at baseline and at 2 days and then 1 year after the initiation of bosentan. Because a remarkable elevation of mixed venous oxygen saturation was observed at the initiation of bosentan, the dosage of EPO was reduced in 7 patients (from 99,6 ± 43.4 to 82.8 ± 31.3 ng · kg-1 · minl, p

AB - Background Combination therapy has been proposed in treatment algorithms for idiopathic pulmonary arterial hypertension (IPAH), so the additional effects of bosentan in IPAH patients already treated with high-dose cpoprostcnol (EPO) was evaluated in the present study. Methods and Results Bosentan (62.5 mg twice daily) was administered to 8 IPAH patients already being treated with high-dose EPO (average dose 99.6 ± 43.4 ng · kg-1 · min-1). Hemodynamics were assessed at baseline and at 2 days and then 1 year after the initiation of bosentan. Because a remarkable elevation of mixed venous oxygen saturation was observed at the initiation of bosentan, the dosage of EPO was reduced in 7 patients (from 99,6 ± 43.4 to 82.8 ± 31.3 ng · kg-1 · minl, p

KW - Bosentan

KW - Combination therapy

KW - Epoprostenol

KW - Idiopathic pulmonary arterial hypertension

UR - http://www.scopus.com/inward/record.url?scp=46849106308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46849106308&partnerID=8YFLogxK

U2 - 10.1253/circj.72.1142

DO - 10.1253/circj.72.1142

M3 - Article

C2 - 18577825

AN - SCOPUS:46849106308

VL - 72

SP - 1142

EP - 1146

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 7

ER -